The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-2927-8
Abstract: The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (CIPN) symptoms; (2) its association with sociodemographic and clinical characteristics; and (3) treatment dose modifications and its influence on the magnitude of… read more here.
Keywords: population based; magnitude neurotoxicity; multiple myeloma; patients multiple ... See more keywords
A single institution experience with palbociclib toxicity requiring dose modifications
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4606-9
Abstract: PurposeSince the widespread implementation of adding palbociclib to endocrine therapy in clinical practice, myelosuppression is becoming increasingly recognized as a toxicity that may lead to dose modification. We aimed to characterize toxicities observed with palbociclib… read more here.
Keywords: palbociclib; palbociclib dose; dose modification; toxicity ... See more keywords
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221075224
Abstract: Introduction The COVID-19 pandemic has introduced new challenges to healthcare access and delivery. It is critical to identify areas for innovation within oncologic clinical practice to maintain high quality care. We evaluated the potential utility… read more here.
Keywords: administration; exam role; role determining; exam ... See more keywords
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1021662
Abstract: The prognosis of chronic myelogenous leukemia (CML-CP) in chronic phase has improved dramatically since the introduction of imatinib. In addition to imatinib, second- and third-generation tyrosine kinase inhibitors (TKIs) and a novel allosteric inhibitor, asciminib,… read more here.
Keywords: chronic myelogenous; myelogenous leukemia; kinase inhibitors; therapy ... See more keywords